https://www.selleckchem.com/pr....oducts/lanifibranor-
The meta-analysis on the risk of failures documented a risk of failures of 7% in the CMI and of 9% in the Actifit group. There is a growing interest on the results of meniscal scaffolds, with most studies published recently. However, long-term data on the Actifit scaffold and high-level comparative studies are missing. Both CMI and Actifit offered good clinical results with a significant and comparable improvement in symptoms and function, and with a low number of failures over time. Accordingly, with the proper indication,
Like
Comment
Share
